Jason Mast and Adam Feuerstein

BioTech

Perplexing results from Duchenne muscular dystrophy trial raise questions about gene therapies

Confounding data from a Pfizer clinical trial has rattled the field of gene therapy for Duchenne muscular dystrophy, raising more questions about the regulatory standard

Jason Mast and Adam Feuerstein October 21, 2024

BioTech

After Sarepta trial failure, families and doctors brace for another debate on Duchenne therapy

To hear Sarepta CEO Doug Ingram tell it, the results Monday afternoon from a large trial of its gene therapy for Duchenne muscular dystrophy marked

Jason Mast and Adam Feuerstein November 1, 2023

BioTech

Sarepta’s Duchenne gene therapy fails to meet primary endpoint in pivotal trial

Sarepta Therapeutics said Monday afternoon that its gene therapy for Duchenne muscular dystrophy failed to improve muscle function compared to a placebo in a large

Jason Mast and Adam Feuerstein October 30, 2023

BioTech

FDA grants conditional approval to Sarepta’s gene therapy for Duchenne muscular dystrophy

The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients,

Jason Mast and Adam Feuerstein June 22, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.

Jason Mast and Adam Feuerstein

Perplexing results from Duchenne muscular dystrophy trial raise questions about gene therapies

After Sarepta trial failure, families and doctors brace for another debate on Duchenne therapy

Sarepta’s Duchenne gene therapy fails to meet primary endpoint in pivotal trial

FDA grants conditional approval to Sarepta’s gene therapy for Duchenne muscular dystrophy

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

Subscribe